Research Summary

Zoe Quandt, MD MS, is an endocrinologist and physician scientist. Her research and clinical care is focused on understanding endocrine side effects of cancer care, particularly immune related adverse events from cancer immunotherapy. She leads the UCSF Metabolic and Endocrine Cancer Immunotherapy Toxicity (MEND-IT) Clinic.

Education

BA, - Biology, Brown University
Residency, - Internal Medicine, Stanford Hospital and Clinics
MS, - Health and Medical Sciences, UC Berkeley
Fellowship, - Endocrinology and Diabetes, UCSF
MD, - Medical School, UCSF

Selected Publications

  1. C.W. Thorball, Z. Quandt, A. Saha, L. Yao, P. Midda, Y. Xu, C.A. Bejan, F. Hodel, A. Stravodimou, E. Shearer-Kang, M. Aldrich, E.J. Philips, G. Liu, A. Schoenfeld, D. Johnson, E. Ziv, J. Fellay, R. Mohindra, J.M. Balko, G.S. Chandler. 67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity. Annals of Oncology. 2024 Sep 1; 35:s240-s241.  View on PubMed
  2. Quandt Z, Perdigoto A, Anderson MS, Herold KC. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harb Perspect Med. 2024 Jul 22.  View on PubMed
  3. Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response. BJC Rep. 2024 Jun 24; 2(1):46.  View on PubMed
  4. Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Princess Margaret Lung Group, Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. medRxiv. 2024 Jun 11.  View on PubMed
  5. Kirkpatrick B Fergus, Pooja Middha, Zoe Quandt, Yiwey Shieh, Amrita B Basu, Rosalyn Sayaman, Paula R Pohlmann, Douglas Yee, Rebecca Arielle Shatsky, Claudine Isaacs, Michael J. Campbell, Gillian L. Hirst, Lamorna Brown Swigart, Laura van 't Veer, Elad Ziv, Laura Esserman. Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):10600-10600.  View on PubMed
  6. Zoe Quandt, Christian Thorball, Pooja Middha, Douglas Buckner Johnson, Cosmin A Bejan, Lydia Yao, Yaomin Xu, Flavia Hodel, Athina Stravodimou, Esther Shearer-Kang, Geoffrey Liu, Melinda C Aldrich, Adam Jacob Schoenfeld, Elad Ziv, Elizabeth J Phillips, Jacques Fellay, Ewa A Bergmann, G Scott Chandler, Justin M Balko, Ashis Saha. HLA associations with immunotherapy related endocrine toxicity. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):2516-2516.  View on PubMed
  7. Rita Nanda, Ronald Cohen, Zoe Quandt, Amrita B Basu, Christina Yau, Amy Jo Chien, Lajos Pusztai, Hyo S. Han, Erica Michelle Stringer-Reasor, Claudine Isaacs, Dawn L. Hershman, Rebecca Arielle Shatsky, Jane Perlmutter, Douglas Yee, Angela DeMichele, Laura van 't Veer, Nola Hylton, Laura Esserman, Hope S. Rugo. Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):584-584.  View on PubMed
  8. Saya Jacob, Samantha Fisch, Carolyn Face, Laura Huppert, Zoe Quandt, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Anne Blaes, Hope Rugo. Abstract PS14-03: Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. Cancer Research. 2024 May 2; 84(9_Supplement):ps14-03-ps14-03.  View on PubMed
  9. Duvalyan E, Brondfield S, Rushakoff RJ, Anderson MS, Quandt Z. Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study. Cancers (Basel). 2024 Apr 25; 16(9).  View on PubMed
  10. Johnson MB, Ogishi M, Domingo-Vila C, De Franco E, Wakeling MN, Imane Z, Resnick B, Williams E, Galão RP, Caswell R, Russ-Silsby J, Seeleuthner Y, Rinchai D, Fagniez I, Benson B, Dufort MJ, Speake C, Smithmyer ME, Hudson M, Dobbs R, EXE-T1D consortium, Quandt Z, Hattersley AT, Zhang P, Boisson-Dupuis S, Anderson MS, Casanova JL, Tree TI, Oram RA. Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency. J Exp Med. 2024 Jun 03; 221(6).  View on PubMed
  11. Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. Nat Commun. 2024 Mar 26; 15(1):2568.  View on PubMed
  12. Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Princess Margaret Lung Group, Matthew A. Gubens, Christine M. Lovly, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv. Abstract 3460: Predicting cessation of immune checkpoint inhibitor therapy due to severe adverse events with an integrated autoimmune disease polygenic risk score. Cancer Research. 2024 Mar 22; 84(6_Supplement):3460-3460.  View on PubMed
  13. Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R, Schwartzberg L, Broder MS. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ Breast Cancer. 2024 Jan 31; 10(1):12.  View on PubMed
  14. Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1242830.  View on PubMed
  15. Silverstein J, Wright F, Wang M, Young A, Kim D, De Dios K, Brondfield S, Quandt Z. Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. Oncologist. 2023 10 03; 28(10):e950-e959.  View on PubMed
  16. Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. medRxiv. 2023 Sep 13.  View on PubMed
  17. Gomes-Lima CJ, Zhou W, Quandt Z. Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects? Front Endocrinol (Lausanne). 2023; 14:1268402.  View on PubMed
  18. Sharon E, Othus M, Quandt ZE. Signal detection in real-world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having. Cancer. 2023 09 15; 129(18):2769-2770.  View on PubMed
  19. Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo. Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):e24091-e24091.  View on PubMed
  20. Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt. The cognitive load of inpatient consults involving immune-related adverse events. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):11033-11033.  View on PubMed

Go to UCSF Profiles, powered by CTSI